1Karen L. Furie,Scott E. Kasner,Robert J. Adams,Gregory W. Albers,Ruth L. Bush,Susan C. Fagan,Jonathan L. Halperin,S. Claiborne Johnston,Irene Katzan,Walter N. Kernan,Pamela H. Mitchell,Bruce Ovbiagele,Yuko Y. Palesch,Ralph L. Sacco,Lee H. Schwamm,Sylvia Wassertheil-Smoller,Tanya N. Turan,Deidre Wentworth,李海峰(译),刘涛(译),杨潘(译),王鹏(译).卒中或短暂性脑缺血发作患者的卒中预防指南 美国心脏协会／美国卒中协会为医疗卫生专业人员制定的指南[J].国际脑血管病杂志,2011,19(1):1-49. 被引量：392
2Cantin B, Despres JP, Lamarche B, et al. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men(The Quebec Cardiovascular Study)[J]. Am J Cardiol, 2002,89:662-666.
3Terres W, Tatsis E, Pfalzer B, et al. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein (a)[J]. Circulation, 1995,82:711.
4Batalla A, Reguero JR, Cubero GI, et al. Plasma lipoprotein(a) and severity of angiographic coronary artery disease[J]. J Am Coll Cardiol, 1999,33:590.
5Schwertner HA, Jackson WG, tolan G. Association of low serum concentration of bilirubin with increased risk of coronary heart disease[J]. Clin Chem, 1997,43(1):18-23.
6Marilena G. New physiological importance of two classic residual products: carbon monoxide and bilirubin [J]. Biochem Mol Med, 1997,61(2):136-142.
7Siow RC, Sato H, Mann GE. Heme oxygenase-carbon monoxide signaling pathway in atherosderosis: anti-atherogeniogenic actions of bilirubin and carbon monoxide[J]. Cardiovase Res, 1999,41(2):385-394.
